Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging.


Journal Article

OBJECTIVE: To evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs). METHODS: Florbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative. RESULTS: Florbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty-four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status. CONCLUSIONS: : The data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.

Full Text

Duke Authors

Cited Authors

  • Johnson, KA; Sperling, RA; Gidicsin, CM; Carmasin, JS; Maye, JE; Coleman, RE; Reiman, EM; Sabbagh, MN; Sadowsky, CH; Fleisher, AS; Murali Doraiswamy, P; Carpenter, AP; Clark, CM; Joshi, AD; Lu, M; Grundman, M; Mintun, MA; Pontecorvo, MJ; Skovronsky, DM; AV45-A11 study group,

Published Date

  • October 2013

Published In

Volume / Issue

  • 9 / 5 Suppl

Start / End Page

  • S72 - S83

PubMed ID

  • 23375563

Pubmed Central ID

  • 23375563

Electronic International Standard Serial Number (EISSN)

  • 1552-5279

Digital Object Identifier (DOI)

  • 10.1016/j.jalz.2012.10.007


  • eng

Conference Location

  • United States